Conclusions and Relevance: The current evidence underscores the potential of GLP-1 RAs as a novel therapeutic approach for certain psychiatric disorders, particularly alcohol-related disorders, depression, and autism-related food behaviors
Expect the stomach side effects to come back after the switch, since the new drug works the receptors a little differently, so the smart move is to restart low and step up rather than match the old dose
A novel G protein-biased and subtype-selective agonist for a G protein-coupled receptor discovered from screening herbal extracts
Giving these specifics turns a vague concern into a clear basis for them to respond with concrete guidance
The overlapping side effects and cardiovascular concerns
As the insulinotropic capacity of GLP-1 is partially retained in diabetic humans, GLP-1-based treatments have been successfully developed